Get the Stockscreener App
89.46
1.46%
-1.33
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $89.46, with a volume of 12.85M.
It is down -1.46% in the last 24 hours and down -12.62% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$90.79
Open:
$91
24h Volume:
12.85M
Relative Volume:
1.09
Market Cap:
$155.82B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.92
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-1.83%
1M Performance:
-12.62%
6M Performance:
-27.63%
1Y Performance:
-31.65%
1-Day Range:
$89.14
$91.00
1-Week Range:
$89.14
$94.79
52-Week Range:
$89.14
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
89.46 | 155.82B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
294.73 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
80.00 | 102.71B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.50 | 83.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.98 | 48.42B | 6.30B | 1.07B | 1.34B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Horizon Investments LLC Sells 48,862 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Offers Growth Potential and High Dividends - HarianBasis.co
Abbott Laboratories $ABT Stock Holdings Lowered by CENTRAL TRUST Co - MarketBeat
ABT: Abbott Laboratories Director Acquires 10,000 Shares Amid De - GuruFocus
Strs Ohio Decreases Stake in Abbott Laboratories $ABT - MarketBeat
PFA Pension Forsikringsaktieselskab Makes New Investment in Abbott Laboratories $ABT - MarketBeat
This Dividend King's Yield Hasn't Been This High in a Decade. Is It a Buy? - The Globe and Mail
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
1 Magnificent Dividend Stock Down 30% to Buy and Hold Forever - The Motley Fool
AI Models Split on Abbott Laboratories (ABT) as Fundamentals Clash With Technical and Valuation Concerns - TipRanks
Abbott Laboratories (ABT) Receives FDA Clearance and CE Mark for Next-Generation Ultreon™ 3.0 Software - Yahoo Finance
Abbott–Exact Sciences, BioMarin–Amicus among deals cleared in Japan in Q1 - MLex
symbol__ Stock Quote Price and Forecast - CNN
How Investors Are Reacting To Abbott (ABT) Gaining FDA, CE Clearance For AI-Guided Ultreon 3.0 - Yahoo Finance
Abbott Laboratories stock hits 52-week low at $90.72 - Investing.com
Abbott Laboratories stock hits 52-week low at $90.72 By Investing.com - Investing.com Australia
FDA Reports Baby Formula Safety, Highlights Abbott (ABT) Among C - GuruFocus
Abbott Laboratories (FRA:ABL0) Stock Price, Trades & News - GuruFocus
Abbott Receives FDA Clearance, CE Mark for Ultreon 3.0 AI Imaging Platform - AIM Media House
ABT SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Abbott Laboratories (ABT) Stock Price, Trades & News - GuruFocus
FDA search for baby formula contamination finds little - Crain's Chicago Business
Abbott Laboratories (ABT) EVP reports 5,314-share trust move - Stock Titan
Vanguard reports 130.7M shares in Abbott Laboratories (ABT) — 7.5% stake - Stock Titan
Ultreon 3.0 regulatory milestone sees Abbott Laboratories stock down 2.64% amid oversold conditions - Traders Union
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
Lawsuit Claims Abbott, Boston Scientific SCS Pre-Market Approval Supplements Caused Permanent Injuries - AboutLawsuits.com
Fund Update: 1,400,797 ABBOTT LABORATORIES (ABT) shares added to FLOSSBACH VON STORCH SE portfolio - Quiver Quantitative
Abbott Laboratories Stock: Why Analysts Rate a Buy in 2026 - TIKR.com
Abbott’s Ultreon 3.0 AI Imaging Clearance And What It Means For Valuation - simplywall.st
Abbott’s FDA-Cleared Ultreon 3.0 Redefines Imaging in Coronary Interventions - The Indian Practitioner
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott By Investing.com - Investing.com Canada
Tuesday’s insider activity: Major sells at Avis Budget, buys at Abbott - Investing.com
Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1 - Yahoo Finance
Major Insider Move Signals Growing Confidence at Abbott Laboratories - TipRanks
Abbott (NYSE: ABT) awards director 2,286 restricted stock units - Stock Titan
Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding - Stock Titan
Abbott Laboratories director Daniel Starks buys $926,537 in shares - Investing.com
Abbott Laboratories director Daniel Starks buys $926,537 in shares By Investing.com - Investing.com India
[Form 4] ABBOTT LABORATORIES Insider Trading Activity - Stock Titan
Abbott Laboratories (NYSE: ABT) director receives 2,286-share restricted stock unit award - Stock Titan
Abbott Laboratories (ABT) director gets RSU and option awards - Stock Titan
Abbott Laboratories (NYSE: ABT) grants shares and stock options to director - Stock Titan
Abbott (NYSE: ABT) director Darren McDew receives 2,286-share RSU award - Stock Titan
Abbott Laboratories (NYSE: ABT) director gets 2,286-share stock unit grant - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) awarded 2,286 share-linked units - Stock Titan
Abbott Laboratories (NYSE: ABT) grants director 2,286 RSUs - Stock Titan
Director at Abbott Laboratories (NYSE: ABT) receives 2,286-share stock grant - Stock Titan
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Abbott Laboratories (NYSE: ABT) director awarded 2,286 RSUs - Stock Titan
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.47%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):